Skip to main content
SpringerLink
Log in

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy

  • Review
  • Published:
European Journal of Dermatology

Abstract

New onset or exacerbation of pre-existing psoriasis after therapeutic TNF-α inhibition is a well-described phenomenon. Over the last two decades, similar cases of paradoxical psoriasis have been reported following the administration of other biologic agents. We aimed to review all published cases of induced or exacerbated psoriasis after biologic therapy other than anti-TNF-α agents in order to further elucidate the pathophysiology of this phenomenon. A systematic literature review in the Medline database regarding any relevant case series or case reports on new onset or exacerbation of psoriasis after the administration of biologic agents targeting B cells, T cell co-stimulation, interleukin-1, interleukin-6, interleukin-17 and interleukin-12/23 was performed using appropriate key words. The literature search revealed nine articles (nine cases) of paradoxical psoriasis after ustekinumab and eight articles (nine cases) after secukinumab administration, both of which are approved therapies for psoriasis Moreover, 15 articles (23 cases) for rituximab, nine articles (12 cases) for abatacept, eight articles (nine cases) for tocilizumab, and one case report for anakinra have been published. In the majority of cases, patients had no prior history of psoriasis while 18 patients presented with exacerbation of pre-existing psoriatic lesions. Paradoxical psoriasis is not a specific adverse event of TNF-α inhibitors but is a possible side effect of any biologic agent interfering with the immune system. Awareness among physicians regarding early recognition is mandatory. Further clinical and experimental data are needed in order to unravel the pathophysiology of this unexpected phenomenon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol 2019; 10: 282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol 2009; 61: 486–504.

    Article  CAS  PubMed  Google Scholar 

  3. Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol 2017; 56: 1087–102.

    Article  PubMed  Google Scholar 

  4. Nidegger A, Mylonas A, Conrad C. [Paradoxical psoriasis induced by anti-TNF — a clinical challenge]. Rev Med Suisse 2019; 15: 668–71.

    PubMed  Google Scholar 

  5. Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L. Psoriasis induced by anti-tumor necrosis factor alpha agents: A comprehensive review of the literature. Acta Dermatovenerologica Croat 2016; 24: 169–74.

    CAS  Google Scholar 

  6. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009; 20: 100–8.

    Article  CAS  PubMed  Google Scholar 

  7. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56: 2715–8.

    Article  CAS  PubMed  Google Scholar 

  8. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008; 67: 1056–7.

    Article  CAS  PubMed  Google Scholar 

  9. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009; 27: 996–8.

    CAS  PubMed  Google Scholar 

  10. Brunasso AMG, Massone C. Plantar pustulosis during rituximab therapy for rheumatoid arthritis. J Am Acad Dermatol 2012; 67: e148–50.

    Article  PubMed  Google Scholar 

  11. Thomas L, Canoui-Poitrine F, Gottenberg J-E, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 2012; 39: 893–8.

    Article  CAS  PubMed  Google Scholar 

  12. Hardcastle SA, Gibbs S, Williamson L. Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol 2012; 39: 1303–4.

    Article  PubMed  Google Scholar 

  13. Guidelli GM, Fioravanti A, Rubegni P, Feci L. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 2013; 33: 2927–30.

    Article  CAS  PubMed  Google Scholar 

  14. Toussirot É. New onset of psoriasis in a patient with rheumatoid arthritis treated with rituximab. J Rheumatol 2013; 40: 1230–1.

    Article  PubMed  Google Scholar 

  15. Ozen G, Ergun T, Oner SY, Demirkesen C, Inanc N. Widespread psoriasis induced by rituximab in a patient with rheumatoid arthritis: an unexpected adverse reaction. Jt bone spine 2013; 80: 545–7.

    Article  Google Scholar 

  16. Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor-a inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol 2014; 171: 1546–9.

    Article  CAS  PubMed  Google Scholar 

  17. Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant. Pediatr Dermatol 2014; 31: e149–51.

    Article  PubMed  Google Scholar 

  18. Mok MMY, Yeung CK, Chan DTM, Lo WK. New onset psoriasis after rituximab for treatment of idiopathic membranous nephropathy. Nephrology (Carlton) 2014; 19: 60.

    Article  CAS  Google Scholar 

  19. Venables ZC, Swart SS, Soon CS. Palmoplantar pustulosis secondary to rituximab: A case report and literature review. Clin Exp Dermatol 2015; 40: 451–2.

    Article  CAS  PubMed  Google Scholar 

  20. Kim D-W, Park S-K, Woo S-H, Yun S-K, Kim H-U, Park J. New-onset psoriasis induced by rituximab therapy for non-Hodgkin lymphoma in a child. Eur J Dermatol 2016; 26: 190–1.

    Article  CAS  PubMed  Google Scholar 

  21. Alahmari HS, Alhowaish NY, Omair MA. Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab. Case Rep Rheumatol 2019; 2019: 5450863. doi: https://doi.org/10.1155/2019/5450863.

    PubMed  PubMed Central  Google Scholar 

  22. Jost C, Hermann J, Caelen LES, Graninger W. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep 2009; 2009. doi: https://doi.org/10.1136/bcr.09.2008.0845.

  23. Florent A, Albert C, Giacchero D, Roux C, Euller-Ziegler L. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Jt bone spine 2010; 77: 626–7.

    Article  Google Scholar 

  24. Kato K, Satoh T, Nishizawa A, Yokozeki H. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 2011; 91: 362–3.

    Article  CAS  PubMed  Google Scholar 

  25. Brigant F, Clavel G, Chatelain D, Lok C, Chaby G. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J 2011; 17: 11.

    Article  CAS  PubMed  Google Scholar 

  26. Silverman D, Oliver A. Abatacept-induced psoriasis. Cutis 2011; 88: 117–8.

    PubMed  Google Scholar 

  27. Konsta M, Rallis E, Karameris A, Stratigos A, Sfikakis PP, Iliopoulos A. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol 2012; 26: 257–8.

    Article  CAS  PubMed  Google Scholar 

  28. Conde-Montero E, Baniandrés-Rodríguez O, Mendoza-Cembranos M, Horcajada-Reales C, Suárez-Fernández R. Psoriasiform reactions during treatment with abatacept. Indian J Dermatol Venereol Leprol 2014; 80: 92–3.

    Article  PubMed  Google Scholar 

  29. Tanita K, Fujimura T, Kakizaki A, Furudate S, Kusakari Y, Aiba S. Psoriasiform drug eruption caused by abatacept: Immunohistochemical investigation of STAT signaling. Case Rep Dermatol 2015; 7: 166–70.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ueda-Hayakawa I, Nguyen Thi Hong C, Ueki Y, Kambe N, Okamoto H. Psoriatic skin lesions induced by abatacept: Case report and review of the published work. J Dermatol 2017; 44: 845–6.

    Article  PubMed  Google Scholar 

  31. Laurent S, Le Parc JM, Clérici T, Bréban M, Mahé E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010; 163: 1364–5.

    Article  CAS  PubMed  Google Scholar 

  32. Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol 2012; 39: 657.

    Article  PubMed  Google Scholar 

  33. Grasland A, Mahé E, Raynaud E, Mahé I. Psoriasis onset with tocilizumab. Jt Bone Spine 2013; 80: 541–2.

    Article  Google Scholar 

  34. Sparsa L, Afif N, Bularca S, et al. [Paradoxical cutaneous reactions associated with tocilizumab therapy]. La Rev Med interne 2014; 35: 613–6.

    Article  CAS  Google Scholar 

  35. Palmou-Fontana N, Sánchez Gaviño JA, McGonagle D, García-Martinez E, Iñiguez de Onzoño Martín L. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology 2014; 228: 311–3.

    Article  CAS  PubMed  Google Scholar 

  36. Sehgal R, Stratman EJ, Cutlan JE. Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience. Clin Med Res 2018; 16: 41–6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hayakawa M, Izumi K, Higashida-Konishi M, et al. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatol Int 2019; 39: 161–6.

    Article  PubMed  Google Scholar 

  38. Matsushima Y, Hayashi A, Mizutani K, et al. Psoriasiform Dermatitis Developing during Treatment of Juvenile Idiopathic Arthritis with Tocilizumab. Case Rep Dermatol 2019; 11: 317–21.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatology 2019; 21: 104–5.

    Google Scholar 

  40. Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat 2012; 23: 212–4.

    Article  CAS  PubMed  Google Scholar 

  41. Safa G, Martin A, Darrieux L. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. J Clin Rheumatol 2011; 17: 385–6.

    Article  PubMed  Google Scholar 

  42. Caca-Biljanovska N, V’lckova-Laskoska M, Laskoski D. Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation. Acta Dermatovenerol Croat 2013; 21: 202–4.

    PubMed  Google Scholar 

  43. Hay RAS, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 2014; 39: 751–2.

    Article  CAS  PubMed  Google Scholar 

  44. Lee HY, Woo CH, Haw S. Paradoxical flare of psoriasis after ustekinumab therapy. Ann Dermatol 2017; 29: 794–5.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Suh HY, Ahn JY, Park MY, Youn JIl. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy. J Dermatol 2018; 45: 332–3.

    Article  PubMed  Google Scholar 

  46. Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int 2018; 38: 1297–9.

    Article  CAS  PubMed  Google Scholar 

  47. Darwin E, Deshpande A, Lev-Tov H. Development of Drug-Induced Inverse Psoriasis in a Patient with Crohn’s Disease. ACG case reports J 2018; 5: e47.

    Article  Google Scholar 

  48. Noell C, McQuade B, Gottlieb A, Rosmarin D. Anti IL-17 flared psoriasis in a patient on secukinumab. Dermatol Ther 2017; 30. doi: https://doi.org/10.1111/dth.12505.

  49. Sladden MJ, Sladden CS, Gulliver WPF. Secukinumab-induced psoriasiform eruption. JAMA Dermatology 2017; 153: 1194–5.

    Article  PubMed  Google Scholar 

  50. Su P, Pan JY. Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab. Dermatologica Sin 2017; 35: 112–3.

    Article  Google Scholar 

  51. Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 2019; 44: 72–3.

    Article  CAS  PubMed  Google Scholar 

  52. Hoshina D, Haga N, Furuya K, Sakai M. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab. Clin Exp Dermatol 2018; 43: 718–9.

    Article  CAS  PubMed  Google Scholar 

  53. Prussick L, Noell C, Her M, Alomran A, Abudu M, Rosmarin D. Two cases of anti-interleukin-17 flared psoriasis. J Am Acad Dermatol 2018. doi: https://doi.org/10.1016/j.jaad.2018.05.1203.

  54. Abbruzzese A, Venerito V, Lopalco G, Fornaro M, Giannotta M, Iannone F. Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. J Clin Rheumatol 2019. doi: https://doi.org/10.1097/RHU.0000000000001076.

  55. Currado D, Margiotta DPE, Conforti C, et al. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scand J Rheumatol 2020; 49: 75–6.

    Article  CAS  PubMed  Google Scholar 

  56. González-López MA, Martínez-Taboada VM, González-Vela MC, Fernández-Llaca H, Val-Bernal JF. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008; 158: 1146–8.

    Article  PubMed  Google Scholar 

  57. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol 2018; 9: 2746.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950–7.

    Article  CAS  PubMed  Google Scholar 

  59. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14: 585–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev 2015; 26: 25–33.

    Article  CAS  PubMed  Google Scholar 

  61. Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 2016; 38: 11–27.

    Article  CAS  PubMed  Google Scholar 

  62. Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med 2014; 4. doi: https://doi.org/10.1101/cshperspect.a015354.

  63. Conrad C, Meller S, Gilliet M. Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. Semin Immunol 2009; 21: 101–9.

    Article  CAS  PubMed  Google Scholar 

  64. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 2014; 192: 3111–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174: 3695–702.

    Article  CAS  PubMed  Google Scholar 

  67. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 2009; 87: 523–36.

    Article  CAS  Google Scholar 

  68. Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018; 9: 25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Palucka AK, Blanck J-P, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN- in autoimmune diseases. Proc Natl Acad Sci 2005; 102: 3372–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Stockenhuber K, Hegazy AN, West NR, et al. Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8+ T cell response. J Exp Med 2018; 215: 1987–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermosifiliogr 2018; 109: 791–800.

    Article  CAS  PubMed  Google Scholar 

  73. Puig L. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. Curr Probl Dermatology 2017; 53: 49–63.

    Article  Google Scholar 

  74. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 2016; 137: 19–27.

    Article  CAS  PubMed  Google Scholar 

  75. Frischknecht L, Vecellio M, Selmi C. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19886505. doi: https://doi.org/10.1177/1759720X19886505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Blok S, Vissers WHPM, Van Duijnhoven M, Van De Kerkhof PCM. Aggravation of psoriasis by infections: A constitutional trait or a variable expression? Eur J Dermatology 2004; 14: 259–61.

    CAS  Google Scholar 

  77. Brzewski PŁ, Spałkowska M, Podbielska M, et al. The role of focal infections in the pathogenesis of psoriasis and chronic urticaria. Postep Dermatologii i Alergol 2013; 30: 77–84.

    Article  Google Scholar 

  78. Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review. J Autoimmun 2014; 55: 10–23.

    Article  CAS  PubMed  Google Scholar 

  79. Avdeev AS, Novikov AA, Aleksandrova EN, Panasiuk EI, Nasonov EL. [The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis]. Klin Med (Mosk) 2014; 92: 28–34.

    CAS  Google Scholar 

  80. Wang A, Bai YP. Dendritic cells: The driver of psoriasis. J Dermatol 2020; 47: 104–13.

    Article  PubMed  Google Scholar 

  81. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66: 700–3.

    Article  CAS  PubMed  Google Scholar 

  82. Samoud-El Kissi S, Galai Y, Sghiri R, et al. BAFF is elevated in serum of patients with psoriasis: Association with disease activity. Br J Dermatol 2008; 159: 765–8.

    Article  CAS  PubMed  Google Scholar 

  83. Ng LG, Sutherland APR, Newton R, et al. B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells. J Immunol 2004; 173: 807–17.

    Article  CAS  PubMed  Google Scholar 

  84. Sutherland APR, Ng LG, Fletcher CA, et al. BAFF Augments Certain Th1-Associated Inflammatory Responses. J Immunol 2005; 174: 5537–44.

    Article  CAS  PubMed  Google Scholar 

  85. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A 2010; 107: 1524–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165: 990–6.

    Article  CAS  PubMed  Google Scholar 

  87. Fritz Y, Klenotic PA, Swindell WR, et al. Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C + IL-6KO Mice. J Invest Dermatol 2017; 137: 696–705.

    Article  CAS  PubMed  Google Scholar 

  88. Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol 2016; 175: 892–901.

    Article  CAS  PubMed  Google Scholar 

  89. Conti HR, Gaffen SL. IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans. J Immunol 2015; 195: 780–8.

    Article  CAS  PubMed  Google Scholar 

  90. Bekeredjian-Ding I, Stein C, Uebele J. The Innate Immune Response Against Staphylococcus aureus. In: Current Topics in Microbiology and Immunology. Vol 409. Springer Verlag; 2015: 385–418.

  91. Catapano M, Vergnano M, Romano M, et al. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. J Invest Dermatol 2020; 140: 816–826.e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Mercurio L, Failla CM, Capriotti L, et al. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses. PLoS One 2020; 15. doi: https://doi.org/10.1371/journal.pone.0222969.

  93. Loft ND, Skov L, Rasmussen MK, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PLoS One 2018; 13. doi: https://doi.org/10.1371/journal.pone.0192010.

  94. Cabaleiro T, Prieto-Pérez R, Navarro R, et al. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J 2016; 16: 336–40.

    Article  CAS  PubMed  Google Scholar 

  95. Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 2013; 56: 512–8.

    Article  CAS  PubMed  Google Scholar 

  96. Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012; 225: 14–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally

Authors and Affiliations

  1. Joint Rheumatology Program, 1st Department of Propaedeutic Internal Medicine-Rheumatology Unit, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Ag. Thoma 17, 11527, Athens, Greece

    Anastasios Karamanakos, Theognosia Vergou, Stylianos Panopoulos, Maria G. Tektonidou & Petros P. Sfikakis

  2. 1st University Clinic, Department of Dermatology-Venereology, National and Kapodistrian University of Athens, School of Medicine, A. Sygros Hospital, I. Dragoumi 5, 16121, Athens, Greece

    Theognosia Vergou & Alexander J. Stratigos

Authors
  1. Anastasios Karamanakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theognosia Vergou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stylianos Panopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria G. Tektonidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander J. Stratigos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Petros P. Sfikakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theognosia Vergou.

Additional information

Disclosures

Funding sources: none. Conflicts of interest: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karamanakos, A., Vergou, T., Panopoulos, S. et al. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Eur J Dermatol 31, 307–317 (2021). https://doi.org/10.1684/ejd.2021.4056

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2021.4056

Key words

Search

Navigation